John McDevitt,
Chair, Department Biomaterials,
New York University College of Dentistry Bioengineering Institute
John T. McDevitt serves as the Chair for the Department Biomaterials at New York University College of Dentistry, is a member of NYU’s Bioengineering Institute and participates as a faculty member in the NYU Department of Chemical and Biomolecular Engineering within the Tandon School of Engineering. McDevitt is a pioneer in the development of ‘programmable bio-nano-chip’ technologies. He has a strong track record of translating essential bioscience discoveries into real-world clinical practice. In this capacity, he serves as the Scientific Founder for three diagnostic companies. His most recent company, SensoDx, features a universal platform sensor technology with capacity to digitize biological signatures for a broad range of key health conditions. McDevitt and his team has raised over $45M in Federal and Foundation support. His recent research has been sponsored by major programs funded by the National Institute of Dental and Craniofacial Research (NIDCR) division of the National Institutes of Health (NIH), the Bill and Melinda Gates Foundation, Cancer Prevention Research Institute of Texas (CPRIT), the National Aeronautics and Space Administration (NASA), the Army and the United Kingdom’s Home Office Scientific Development Branch.
McDevitt and his team have written more than 200 peer-reviewed scientific manuscripts and have contributed to more than 100 patents and patent applications. This work was recognized with the “2016 AACC Wallace H. Coulter Lectureship Award,” “Best of What's New Award” in the Medical Device Category for 2008 by Popular Science as well as for the “Best Scientific Advances Award” in 1998 by the Science Coalition. Dr. McDevitt’s individual honors include the Presidential Young Investigator Award, the 2010 California Polytechnic Distinguished Alumni Award and the Exxon Education Award. Over the past 7 years, Dr. McDevitt has served as the Principal Investigator for 6 major clinical trials and 2 clinical pilot studies, all involving the programmable bio-nano-chip. Through these clinical efforts, mini-sensor ensembles are being developed for major diseases in the areas of oral cancer, cardiac heart disease, trauma, drugs of abuse, ovarian cancer and prostate cancer.
High Content Single Cell Analysis Using the Programmable Bio-Nano-Chip System: New Tools for Cancer Diagnosis
Wednesday, 6 June 2018 at 10:30
Add to Calendar ▼2018-06-06 10:30:002018-06-06 11:30:00Europe/LondonHigh Content Single Cell Analysis Using the Programmable Bio-Nano-Chip System: New Tools for Cancer DiagnosisPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Over the past few decades, use of biomarkers has become increasingly intrinsic to practice of medicine and clinical decision-making. Diagnosis and management of oral cancer is a promising area whereby biomarker driven testing has potential to provide significant impact on patient care. Oral cancer is sixth most common cancer worldwide and has been marked by high morbidity and poor survival rates with little over the past few decades. Beyond prevention, early detection is the most crucial determinant for successful treatment and survival of oral cancer. This talk will feature details related to a new ‘cytology-on-a-chip’ platform capable of high-content single-cell measurements. This methodology permits concurrent analysis of molecular biomarker expression and cellular/nuclear morphology using over 200 fluorescence intensity and shape parameters for each region of interest extracted from multi-spectral fluorescence images. Molecular biomarkers: EGFR, avß6, CD147, ß-catenin, MCM2, and Ki67 were selected based on their capacity, through prior immunohistochemistry studies, to distinguish stages of disease progression towards oral cancer. Measurement time to complete this chip-based image analysis is approximately 20 minutes vs. about 1-3 days for gold standard pathology exam. This new clinical decision tool has been developed and validated in context of major clinical study involving 714 prospectively recruited patients. These efforts have led to collection of data across 6 diagnostic categories and assembly of one of largest well-qualified cytology database (confirmed by tissue biopsy) ever collected for prospectively recruited potentially malignant oral lesions. The application of statistical machine learning algorithms exploiting this large database has led to development of robust classification models with validated and stable parameters. High sensitivity and high specificity adjunctive diagnostic aids have been developed through these efforts.
Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonPoint-of-Care Diagnostics and Biosensors Europe 2018Point-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-06-06 10:30:002018-06-06 11:30:00Europe/LondonHigh Content Single Cell Analysis Using the Programmable Bio-Nano-Chip System: New Tools for Cancer DiagnosisPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
